DHX15: A Drug Target / Disease Biomarker (G1665)

Target Name: DHX15

NCBI ID: G1665

DHX15

DHX15: A Drug Target / Disease Biomarker

DHX15 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation have been studied extensively in the scientific literature, and its potential as a drug target continues to attract interest and research.

The protein encoded by DHX15 is a member of the homeobox gene family, which is characterized by the presence of a putative DNA-binding domain and a frequent conservation of gene structure across species. DHX15 is unique among its family members, as it is the only known gene that encodes a protein with a predicted transmembrane domain and a conserved nucleotide sequence within its extracellular domain.

The function of DHX15 is not well understood, but its potential involvement in disease is thought to be related to its unique structure and the various functions of its gene product. Several studies have identified DHX15 as a potential drug target or biomarker, based on its expression and localization to various tissues and its potential involvement in various biological processes.

One of the most promising aspects of DHX15 is its potential as a cancer drug target. Several studies have shown that DHX15 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, experiments have shown that inhibition of DHX15 can lead to the growth inhibition and apoptosis of cancer cells. These findings suggest that DHX15 may be an effective target for cancer treatment.

Another potential application of DHX15 is its potential as a neurodegenerative disease drug target. DHX15 has been shown to be expressed in the brains of individuals with various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, experiments have shown that DHX15 interacts with several neurotransmitters, including dopamine, which is involved in the development and progression of neurodegenerative diseases.

In addition to its potential as a cancer and neurodegenerative disease drug target, DHX15 may also be a useful biomarker for these conditions. Several studies have shown that DHX15 can be used as a marker for the diagnosis and monitoring of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, its expression has been shown to be associated with the development of certain neurological disorders, such as ALS and multiple sclerosis.

Despite the potential benefits of DHX15 as a drug target or biomarker, much research is still needed to fully understand its function and regulation. Several studies have identified potential regulatory interactions between DHX15 and other genes, including the TGF-β pathway and the Wnt signaling pathway. However, more research is needed to determine the precise role of DHX15 in these processes and its potential as a drug target or biomarker.

In conclusion, DHX15 is a gene that has generated significant interest and research due to its unique structure and potential involvement in various diseases. Its expression and localization to various tissues make it a promising candidate as a drug target or biomarker. Further research is needed to fully understand its function and regulation and its potential as a drug target or biomarker.

Protein Name: DEAH-box Helicase 15

Functions: RNA helicase involved in mRNA processing and antiviral innate immunity (PubMed:19432882, PubMed:19103666, PubMed:32179686, PubMed:24990078, PubMed:24782566, PubMed:34161762). Pre-mRNA processing factor involved in disassembly of spliceosomes after the release of mature mRNA (PubMed:19103666). In cooperation with TFIP11 seem to be involved in the transition of the U2, U5 and U6 snRNP-containing IL complex to the snRNP-free IS complex leading to efficient debranching and turnover of excised introns (PubMed:19103666). Plays a key role in antiviral innate immunity by promoting both MAVS-dependent signaling and NLRP6 inflammasome (PubMed:24990078, PubMed:24782566, PubMed:34161762). Acts as an RNA virus sensor: recognizes and binds viral double stranded RNA (dsRNA) and activates the MAVS-dependent signaling to produce interferon-beta and interferon lambda-3 (IFNL3) (PubMed:24990078, PubMed:24782566, PubMed:34161762). Involved in intestinal antiviral innate immunity together with NLRP6: recognizes and binds viral dsRNA and promotes activation of the NLRP6 inflammasome in intestinal epithelial cells to restrict infection by enteric viruses (PubMed:34161762). The NLRP6 inflammasome acts by promoting maturation and secretion of IL18 in the extracellular milieu (PubMed:34161762). Also involved in antibacterial innate immunity by promoting Wnt-induced antimicrobial protein expression in Paneth cells (By similarity)

The "DHX15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets